Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3016859 ISA · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| LY3016859 Osteoarthritis ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3016859 or matching placebo |
| LY3016859 Diabetic Neuropathic Pain ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3016859 or matching placebo |
| LY3016859 Chronic Back Pain ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3016859 or matching placebo |
| LY3556050 Osteoarthritis ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3556050 or matching placebo |
| LY3556050 Diabetic Neuropathic Pain ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3556050 or matching placebo |
| LY3556050 Chronic Back Pain ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3556050 or matching placebo |
| LY3526318 Osteoarthritis ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3526318 or matching placebo |
| LY3526318 Diabetic Neuropathic Pain ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3526318 or matching placebo |
| LY3526318 Chronic Back Pain ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3526318 or matching placebo |
| LY3857210 Osteoarthritis ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3857210 or matching placebo |
| LY3857210 Diabetic Neuropathic Pain ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3857210 or matching placebo |
| LY3857210 Chronic Back Pain ISA | EXPERIMENTAL | Participants are randomized to receive either active LY3857210 or matching placebo |
| Name | Type | Description |
|---|---|---|
| LY3016859 ISA | DRUG | Administered intravenously (IV) |
| LY3556050 ISA | DRUG | Administered orally |
| LY3526318 ISA | DRUG | Administered orally |
| LY3857210 ISA | DRUG | Administered orally |
| Placebo Oral | DRUG | Placebo administered orally |
| Placebo | DRUG | Placebo administered IV |
Inclusion Criteria: * have a visual analog scale (VAS) pain value \>40 and \<95 at screening and prerandomization screening. * have a history of daily pain for at least 12 weeks based on participant report or medical history * have a value of ≤30 on the pain catastrophizing scale * have a body mass...
LY3016859 ISA is an investigational small molecule being studied for the treatment of chronic pain conditions, including osteoarthritis of the knee. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
LY3016859 ISA is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
LY3016859 ISA is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved for commercial use. The ongoing Phase 2 trial is actively recruiting participants to assess its effects in chronic pain conditions.
LY3016859 ISA is being evaluated in a Phase 2 master protocol study with the identifier NCT05986292. This trial, titled 'A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain,' is recruiting up to 10,000 participants across the United States and Puerto Rico.
LY3016859 ISA is being studied for chronic pain conditions, specifically osteoarthritis of the knee, diabetic neuropathic pain, and chronic low-back pain. The ongoing Phase 2 trial includes participants aged 18 years and older with these conditions.